 Dermata Therapeutics Inc NASDAQ: DRMA announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic skin conditions. DMT410 showed improvements in pore size, luminosity, brightness, and overall aesthetic appearance. 